Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Published Online: 2019-11-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Bonnie W Ramsey•Bruce Barnett•Charlotte M McKee•Charlotte Teneback•Christiane Knoop•Christof Majoor•Christopher Simard•Cori Daines•Damian G Downey•Damien Downey•Dana Kissner•David Waltz•Deborah K. Froh•Edward F McKone•Edward Nash•Elizabeth Tullis•Elke De Wachter•Eva Van Braeckel•Eva Van Braeckel•Fengjuan Xuan•Floyd Livingston•Francisco J. Calimano•Francois Vermeulen•Gary Connett•Gary Mueller•Gautham Marigowda•Harry G M Heijerman•Harry Heijerman•Herschel Scher•Isabel Neuringer•James Chmiel•Jennifer L Taylor-Cousar•Jennifer L. Taylor-Cousar•Jimmy Johannes•John J Welter•John Welter•Kapilkumar Patel•Karen McCoy•Karen S McCoy•Kathryn Moffett•Larry G. Johnson•Manu Jain•Marcus A Mall•Marleen Bakker•Neil Ahluwalia•Nicholas Withers•Nighat Mehdi•Patricia Macedo•Patrick Flume•Patrick R Sosnay•Petrus Merkus•Raksha Jain•Renske van der Meer•Ronald Rubenstein•Ross Carl Klingsberg•Samuel M Moskowitz•Scott Donaldson•Seth Walker•Steven M Rowe•Stijn Verhulst•Subramanyam Chittivelu•Sudhakar Reddivalam•Thomas Keens•Timothy Lee•Yaohua Zhang
